
ORGO
Organogenesis Holdings Inc.
$4.72
+$0.14(+3.06%)
90
Overall
--
Value
90
Tech
--
Quality
Market Cap
$616.53M
Volume
1.71M
52W Range
$2.61 - $6.71
Target Price
$7.00
Order:
Income Statement
Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||
Total Revenue | $138.7M | $198.5M | $193.4M | $261.0M | $338.3M | $467.4M | $450.9M | $433.1M | $482.0M | ||
Total Revenue | $138.7M | $198.5M | $193.4M | $261.0M | $338.3M | $467.4M | $450.9M | $433.1M | $482.0M | ||
COST OF GOODS SOLD | |||||||||||
Cost of Revenue | $-48.2M | $-61.2M | $-68.8M | $75.9M | $87.3M | $114.2M | $105.0M | $106.5M | $115.7M | ||
GROSS PROFIT | |||||||||||
Gross Profit | $90.5M | $137.3M | $124.6M | $185.0M | $251.0M | $353.2M | $345.9M | $326.7M | $366.3M | ||
OPERATING EXPENSES | |||||||||||
Operating Expenses | $-208.7K | $-142.8M | $-176.2M | $214.5M | $224.3M | $280.9M | $323.6M | $314.1M | $367.6M | ||
Research & Development | -- | $9.1M | $10.7M | $14.8M | $20.1M | $144.9M | $39.8M | $44.4M | $50.3M | ||
Research Expense | -- | $9.1M | $10.7M | $14.8M | $20.1M | $144.9M | $39.8M | $44.4M | $50.3M | ||
Selling, General & Administrative | -- | $133.7M | $162.0M | $199.7M | $204.2M | $250.2M | $283.8M | $269.8M | $294.5M | ||
Selling & Marketing Expenses | -- | $133.7M | $162.0M | -- | -- | -- | -- | -- | -- | ||
General & Administrative Expenses | -- | $-4.0M | $-4.6M | $199.7M | $204.2M | $250.2M | $283.8M | $269.8M | $294.5M | ||
Salaries & Wages | -- | -- | -- | $75.9M | -- | -- | -- | -- | -- | ||
Depreciation & Amortization | -- | $-3.6M | $-3.3M | $3.4M | $4.4M | $5.8M | $5.8M | $10.4M | $13.6M | ||
Depreciation & Amortization | -- | $-3.6M | $-3.3M | $3.4M | $4.4M | $5.8M | $5.8M | $10.4M | $13.6M | ||
Amortization | -- | $-2.0M | $-3.7M | $25.5M | $28.8M | $30.5M | $29.0M | $29.3M | $29.9M | ||
Other Operating Expenses | $208.7K | $-1.2M | $3.5M | $6.2M | $-111.0K | $-153.0K | $-206.0K | $-113.0K | $20.3M | ||
OPERATING INCOME | |||||||||||
Operating income | $-208.7K | $-5.5M | $-51.6M | $-29.5M | $26.7M | $72.2M | $22.3M | $12.5M | $-1.3M | ||
EBITDA | $-14.7M | $-783.0K | $-47.0M | $-21.9M | $37.2M | $87.0M | $40.3M | $34.0M | $22.8M | ||
NON-OPERATING ITEMS | |||||||||||
Interest Expense (Non-Operating) | -- | $8.1M | $10.8M | $9.0M | $11.3M | $7.2M | $2.0M | $137.0K | $197.0K | ||
Intinc | -- | $-908.0K | $-469.0K | $78.0K | -- | -- | -- | -- | -- | ||
Net Non-Operating Interest Income/Expense | -- | $-9.0M | $-11.3M | $-9.0M | $-11.3M | $-7.2M | $2.0M | $-137.0K | $-197.0K | ||
Other Income/Expense | -- | $9.0K | $1.9M | $1.8M | $-2.3M | $1.9M | $-13.0K | $-57.0K | $18.8M | ||
Other Special Charges | -- | $-9.0K | $-1.9M | $-1.8M | $2.3M | $-1.9M | $-13.0K | $57.0K | $20.0K | ||
SPECIAL ITEMS | |||||||||||
Restructring And Mn A Income | -- | $-423.0K | -- | -- | -- | $4.7M | $2.3M | $3.8M | -- | ||
Special Income Charges | -- | $423.0K | -- | -- | $2.2M | $-4.7M | $-2.3M | $-3.8M | -- | ||
Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | $18.8M | ||
PRE-TAX INCOME | |||||||||||
EBIT | $-14.7M | $-6.4M | $-54.0M | $-31.3M | $29.0M | $70.3M | $22.3M | $10.5M | $-2.6M | ||
Pre-Tax Income | $-14.7M | $-14.6M | $-64.7M | $-40.3M | $17.8M | $63.1M | $20.3M | $10.4M | $-2.8M | ||
INCOME TAX | |||||||||||
Tax Provision | -- | $-7.0M | $84.0K | $150.0K | $530.0K | $-31.1M | $4.8M | $5.4M | $-3.7M | ||
NET INCOME | |||||||||||
Net Income | $-208.7K | $-8.4M | $-64.8M | $-40.5M | $17.2M | $94.2M | $15.5M | $4.9M | $861.0K | ||
Net Income (Continuing Operations) | $-208.7K | $-8.4M | $-64.8M | $-40.5M | $17.2M | $94.2M | $15.5M | $4.9M | $861.0K | ||
Net Income (Discontinued Operations) | $-208.7K | $-8.4M | $-64.8M | $-40.5M | $17.2M | $94.2M | $15.5M | $4.9M | $861.0K | ||
Net Income (Common Stockholders) | $-208.7K | $-8.4M | $-64.8M | $-41.1M | $17.2M | $94.2M | $15.5M | $4.9M | $-937.0K | ||
Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | $12.4M | ||
TOTALS | |||||||||||
Total Expenses | $-48.4M | $-204.0M | $-245.0M | $290.4M | $311.6M | $395.1M | $428.6M | $420.6M | $483.3M | ||
SHARE & EPS DATA | |||||||||||
Average Shares Outstanding | $7.9M | $63.9M | $69.3M | $92.8M | $107.7M | $128.3M | $130.1M | $131.2M | $131.7M | ||
Average Shares Outstanding (Diluted) | $7.0M | $64.1M | $69.0M | -- | $111.4M | $133.7M | $132.4M | $132.7M | $131.7M | ||
Shares Outstanding | $126.9M | $38.8M | $92.0M | $105.4M | $128.0M | $128.8M | $131.2M | $132.0M | $126.8M | ||
Basic EPS | -- | $-0.07 | -- | $-0.44 | $0.17 | $0.74 | $0.12 | $0.04 | $-0.01 | ||
Basic EPS (Continuing Operations) | -- | -- | -- | $-0.44 | $0.17 | $0.74 | $0.12 | $0.04 | $-0.01 | ||
Diluted EPS | $-0.03 | $-0.14 | $-0.94 | $-0.44 | $0.16 | $0.71 | $0.12 | $0.04 | $-0.01 | ||
Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $0.16 | $0.71 | $0.12 | $0.04 | $-0.01 | ||
OTHER METRICS | |||||||||||
Accretion On Preferred Stock | -- | -- | -- | -- | -- | -- | -- | -- | $412.0K | ||
Accrued Preferred Stock Dividends | -- | -- | -- | $645.0K | -- | -- | -- | $-4.9M | $937.0K | ||
Acquisition Expense | -- | -- | -- | -- | $87.3M | -- | -- | -- | -- | ||
Gain On Sale Of P P E | -- | $8.0K | $-1.2M | -- | -- | -- | -- | $-559.0K | -- | ||
Loss And Loss Adjustment Expected Incurred | -- | -- | -- | $75.9M | -- | -- | -- | -- | -- | ||
Minority Interests | -- | $-863.0K | -- | -- | -- | -- | -- | -- | -- | ||
Net Income Discontinuous Operations | -- | $418.0K | $1.3M | -- | -- | -- | -- | -- | -- | ||
Non Recurring Operation Expense | -- | -- | -- | -- | $-2.2M | -- | -- | -- | -- | ||
Other Gand A | -- | $-4.0M | $-4.6M | $199.7M | $204.2M | $250.2M | $283.8M | $269.8M | $294.5M | ||
Otherunder Preferred Stock Dividend | -- | -- | -- | $645.0K | -- | -- | -- | $-4.9M | $1.3M | ||
Preferred Stock Dividends | -- | -- | -- | $645.0K | -- | -- | -- | $-4.9M | $1.3M | ||
Provision For Gain Loss On Disposal | -- | $418.0K | $1.3M | -- | -- | -- | -- | -- | -- | ||
Rent And Landing Fees | -- | $-1.8M | $-1.6M | -- | -- | -- | -- | -- | -- | ||
Selling Expense | -- | $133.7M | $162.0M | -- | -- | -- | -- | -- | -- | ||
Write Down | -- | -- | -- | -- | $87.3M | -- | -- | -- | -- | ||
Restruct | -- | $-423.0K | -- | -- | -- | $4.7M | $2.3M | $3.8M | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | ORGO | $4.72 | +3.1% | 1.71M |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Organogenesis Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW